Poninder Kumar1, Ajay Banarji2, Sagarika Patyal3, V S Gurunadh4, T S Ahluwalia5, Avadesh Oli6, P S Moulick1, Anuradha Makker7. 1. Associate Professor, Department of Ophthalmology, Armed Forces Medical College, Pune 40, India. 2. Commandant, Military Hospital Secunderabad, Andhra Pradesh, India. 3. Commandant, 153 General Hospital, C/O -56 APO, India. 4. Consultant (Ophthalmology), Command Hospital (Eastern Command), Kolkatta, India. 5. Professor & Head, Department of Ophthalmology, Armed Forces Medical College, Pune 40, India. 6. Graded Specialist (Ophthalmology), Command Hospital (Air Force), Bangalore, India. 7. Professor (Microbiology), ACMS, Delhi, India.
Abstract
BACKGROUND: A non-randomized, interventional study was carried out various types of retinal venous occlusions with significant macular edema who required an Anti-VEGF injection. METHOD: One hundred and one consecutive patients diagnosed as a case of CRVO/HCRVO/BRVO were enrolled in the study provided they had significant macular edema. Atleast three intra-vitreal injections of Anti-VEGFs were given and both the pre and post injections BCVA and CMT on OCT were observed and analyzed. RESULTS: 87 patients (86.14%) showed a significant improvement of vision of atleast two lines on the Snellen's and mean BCVA improved from log MAR +1.084 to log MAR +0.455. CMT on OCT showed reduction in thickness after Anti-VEGF therapy in 99 patients out of 101 and mean CMT decreased from 586.30 μ at baseline to 329.50 μ. Both of these findings were statistically very significant. CONCLUSIONS: Anti-VEGF therapy had a marked improvement in BCVA along with a dramatic reduction in CMT in the vast majority of RVOs patients with no serious ocular or systemic side effects.
BACKGROUND: A non-randomized, interventional study was carried out various types of retinal venous occlusions with significant macular edema who required an Anti-VEGF injection. METHOD: One hundred and one consecutive patients diagnosed as a case of CRVO/HCRVO/BRVO were enrolled in the study provided they had significant macular edema. Atleast three intra-vitreal injections of Anti-VEGFs were given and both the pre and post injections BCVA and CMT on OCT were observed and analyzed. RESULTS: 87 patients (86.14%) showed a significant improvement of vision of atleast two lines on the Snellen's and mean BCVA improved from log MAR +1.084 to log MAR +0.455. CMT on OCT showed reduction in thickness after Anti-VEGF therapy in 99 patients out of 101 and mean CMT decreased from 586.30 μ at baseline to 329.50 μ. Both of these findings were statistically very significant. CONCLUSIONS: Anti-VEGF therapy had a marked improvement in BCVA along with a dramatic reduction in CMT in the vast majority of RVOs patients with no serious ocular or systemic side effects.
Authors: Diana Iturralde; Richard F Spaide; Catherine B Meyerle; Jay M Klancnik; Lawrence A Yannuzzi; Yale L Fisher; John Sorenson; Jason S Slakter; K Bailey Freund; Michael Cooney; Howard F Fine Journal: Retina Date: 2006-03 Impact factor: 4.256
Authors: Sivakami A Pai; Rohit Shetty; Priya B Vijayan; G Venkatasubramaniam; Naresh K Yadav; Bhujang K Shetty; Rajesh B Babu; Kannan M Narayana Journal: Am J Ophthalmol Date: 2007-02-15 Impact factor: 5.258
Authors: Daniel F Martin; Maureen G Maguire; Gui-shuang Ying; Juan E Grunwald; Stuart L Fine; Glenn J Jaffe Journal: N Engl J Med Date: 2011-04-28 Impact factor: 91.245
Authors: Richard F Spaide; Louis K Chang; James M Klancnik; Lawrence A Yannuzzi; John Sorenson; Jason S Slakter; K Bailey Freund; Robert Klein Journal: Am J Ophthalmol Date: 2008-10-17 Impact factor: 5.258
Authors: T C Kreutzer; C S Alge; A H Wolf; D Kook; J Burger; R Strauss; C Kunze; C Haritoglou; A Kampik; S Priglinger Journal: Br J Ophthalmol Date: 2008-01-22 Impact factor: 4.638
Authors: K Kriechbaum; S Michels; F Prager; M Georgopoulos; M Funk; W Geitzenauer; U Schmidt-Erfurth Journal: Br J Ophthalmol Date: 2008-01-22 Impact factor: 4.638
Authors: Michael S Ip; Justin L Gottlieb; Alon Kahana; Ingrid U Scott; Michael M Altaweel; Barbara A Blodi; Ronald E Gangnon; Carmen A Puliafito Journal: Arch Ophthalmol Date: 2004-08
Authors: Marion Funk; Katharina Kriechbaum; Franz Prager; Thomas Benesch; Michael Georgopoulos; Gerhard J Zlabinger; Ursula Schmidt-Erfurth Journal: Invest Ophthalmol Vis Sci Date: 2008-12-05 Impact factor: 4.799
Authors: Philip Hykin; A Toby Prevost; Sobha Sivaprasad; Joana C Vasconcelos; Caroline Murphy; Joanna Kelly; Jayashree Ramu; Abualbishr Alshreef; Laura Flight; Rebekah Pennington; Barry Hounsome; Ellen Lever; Andrew Metry; Edith Poku; Yit Yang; Simon P Harding; Andrew Lotery; Usha Chakravarthy; John Brazier Journal: Health Technol Assess Date: 2021-06 Impact factor: 4.014